glp-1 news november 2025 today weight loss drug Weight-Loss Drugs Could Address a Range of Addictions GLP-1 Trends: Access & Shortages, – GLP-1R Race in 2025: 8

Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility

Dysbiosis of the gut microbiota can induce metabolic syndromes, inflammation, and hormone dysregulation 37,38,39,40

Glutathione (GSH) enhancement in a concentration-dependent manner (millimolar concentrations) in DC is directly associated with IL-12 production, which in turn favours a Th1 CD4+ T cell response, resulting in the production of IL-2, IL-12, and IFN-

View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Our view The global CDMO market, valued at around US$ 255 billion in 2025, is projected to grow to over US$ 465 billion by 2032

Cell 136: 2636

We dont sell a menu